Integrated DNA Technologies Expands DNA Synthesis Capabilities to Support Genomics Programs Across Scale and Complexity
Integrated DNA Technologies (IDT), a Danaher company and global provider of genomics solutions, has announced an expansion of its DNA synthesis capabilities designed to address the increasingly diverse requirements of customers developing genomic and molecular biology applications. The expanded offering is intended to provide researchers and biotechnology companies with greater flexibility across different levels of DNA synthesis yield, design complexity, production scale and program maturity.
With the expansion, IDT will be able to support a broader range of DNA synthesis requirements, including the rapid production of low-yield, high-diversity oligonucleotides for early-stage research and development, while continuing to provide high-yield and high-fidelity oligonucleotide manufacturing for larger and longer-term programs.
The company said the expanded capabilities will create a more comprehensive DNA synthesis portfolio, allowing customers to select the technology and production approach that best fits their scientific requirements as their programs evolve. The strategy is intended to help customers move from early development to larger-scale applications without sacrificing quality, consistency, reliability or supply continuity.
Supporting the Full Development Lifecycle
Modern genomics programs are becoming increasingly complex, requiring researchers to work with larger numbers of designs, more sophisticated sequences and greater levels of precision. At the same time, development teams are under pressure to accelerate research timelines and transition promising discoveries into clinical, diagnostic or commercial applications.
IDT’s expanded DNA synthesis platform is designed to address these challenges by providing different synthesis capabilities across the development lifecycle.
Early-stage programs may require researchers to evaluate large numbers of DNA sequences or highly diverse designs. In these situations, the ability to rapidly generate a broad range of oligonucleotides can be particularly important. As programs mature, requirements may shift toward higher yields, greater manufacturing consistency and dependable supply for larger-scale applications.
IDT said its expanded portfolio is designed to accommodate this progression, giving customers the flexibility to select appropriate synthesis capabilities as their needs change.
The approach is intended to reduce the need for customers to change suppliers or workflows as programs move from discovery to development and ultimately toward broader-scale production. By connecting different synthesis capabilities within a single platform, IDT aims to provide continuity throughout the lifecycle of a genomics program.
Addressing Increasing Demand for Speed and Flexibility
Jennifer Meade, president of Integrated DNA Technologies, said customers are managing increasingly complex genomic programs that require speed, flexibility and confidence throughout development.
According to Meade, researchers need solutions that can adapt as scientific and operational requirements change without compromising product quality, performance or continuity of supply. IDT’s expanded capabilities are intended to provide this flexibility while maintaining the company’s focus on quality and scalability.
The company’s strategy centers on developing a broad spectrum of synthesis capabilities rather than relying on a single manufacturing approach. This allows IDT to serve customers with different requirements, from highly diverse early-stage designs to more established programs requiring consistent and scalable production.
The expansion also strengthens the company’s ability to support customers as they move through different stages of development and encounter new technical or manufacturing challenges.
Expanding Support for Precision Oncology
The latest initiative also reflects IDT’s continued focus on precision oncology, an area in which genomics and advanced molecular technologies play an increasingly important role.
IDT has supported innovators working on applications such as minimal residual disease (MRD) detection and multi-cancer early detection (MCED). These applications can require sophisticated genomic workflows and high-quality molecular reagents capable of supporting sensitive and reproducible analyses.
By expanding its DNA synthesis capabilities, IDT aims to strengthen its ability to serve organizations developing next-generation diagnostic and research technologies in oncology and other areas of genomics.
The company also expects the expanded offering to contribute to its broader global innovation ecosystem. As genomic research continues to expand across international markets, demand is increasing for reliable DNA synthesis and molecular biology solutions that can support both emerging biotechnology companies and established life sciences organizations.
New Offerings to Expand Customer Choice
IDT said an initial rollout of new products and services will follow the expansion, giving customers access to more flexible and potentially cost-efficient synthesis solutions across a broader range of genomic applications.
The company plans to announce product-specific availability and additional portfolio offerings as they are introduced.
The expanded portfolio is expected to complement IDT’s existing high-yield, high-fidelity oligonucleotide production capabilities. Rather than replacing existing offerings, the new capabilities are intended to broaden the range of options available to customers.
This approach could be particularly valuable for organizations managing multiple projects at different stages of development. A customer may require high-diversity synthesis for exploratory research while simultaneously needing high-yield production for an established program. A broader synthesis platform can provide the flexibility required to address both needs.
Investment in Manufacturing Infrastructure
The DNA synthesis expansion is part of IDT’s broader investment in manufacturing capacity and technological innovation.
Earlier in 2026, the company expanded its synthesis capacity in Coralville, Iowa, by more than threefold. That investment increased the infrastructure available to support growing demand for DNA synthesis and reinforced IDT’s ability to provide scalable manufacturing services.
The company is now adding another component to its innovation strategy through its pilot laboratory at the Innovation Nexus i
8+n Sunnyvale, California.
The pilot lab is designed to increase the speed at which emerging scientific technologies can be evaluated, developed and converted into customer-ready solutions. By bringing innovation activities closer to customers and development teams, IDT expects to accelerate the transition from new scientific concepts to practical products and services.
Together, the Sunnyvale pilot lab and expanded Coralville manufacturing capabilities are intended to create an infrastructure that can support customers across the full development cycle, from early research through larger-scale deployment.
Connecting Innovation With Manufacturing
The combination of research capabilities and expanded manufacturing infrastructure is an important part of IDT’s long-term strategy. Genomics companies often need to move quickly from proof-of-concept research to more structured development programs, creating a need for suppliers that can support both innovation and scale.
IDT’s strategy is designed to bridge that gap by connecting scientific expertise, synthesis technologies, manufacturing capacity and workflow capabilities.
The company believes this integrated model can help customers address challenges related to sequence complexity, production scale, speed and supply continuity. It also provides a framework for introducing new synthesis technologies while maintaining established manufacturing capabilities.
Meade emphasized that customers cannot compromise on speed, complexity, quality or scale when developing modern genomics programs. She said IDT is building a broader capability set that allows customers to use the most appropriate synthesis solution at each stage of their programs.
Enabling Genomics Innovation
DNA synthesis remains a foundational technology across a wide range of applications, including molecular diagnostics, synthetic biology, genomics research, drug discovery and precision medicine. As researchers design increasingly complex genetic constructs and analyze larger numbers of sequences, the need for flexible and scalable synthesis solutions continues to grow.
IDT’s latest expansion is aimed at meeting that demand by providing customers with a wider range of options for DNA and oligonucleotide production.
The ability to rapidly produce diverse designs can help researchers accelerate early experimentation and screening. At later stages, high-yield and high-fidelity production can support programs that require greater quantities and consistent supply.
By offering capabilities across this spectrum, IDT aims to help customers transition more efficiently between stages without compromising the quality or reliability of their molecular inputs.
Supporting Long-Term Program Growth
The company’s expanded DNA synthesis capabilities are also intended to support the long-term evolution of customer programs. As scientific projects mature, their technical requirements often change. Programs that begin with exploratory research may eventually require higher production volumes, more stringent quality controls and dependable long-term supply.
IDT’s full-spectrum approach is designed to provide continuity throughout that progression.
The company said its goal is to create a connected system that allows customers to move from ambitious scientific concepts toward lasting applications with greater speed and confidence. Its investments in synthesis capacity, pilot-scale innovation and portfolio development are intended to strengthen that system.
With expanded synthesis capabilities, new offerings planned for rollout and continued investments in manufacturing and innovation infrastructure, IDT is positioning itself to support the evolving needs of the global genomics market. The initiative represents another step in the company’s strategy to provide flexible, scalable and reliable DNA synthesis solutions for researchers and organizations advancing next-generation genomic applications.
About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT), a Danaher company, has evolved from an oligo manufacturer to a leading genomics solutions provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.
Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; RUO products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD products are intended for diagnostic applications as specified in product documentation.
References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.
Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.